CR20210586A - Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades - Google Patents

Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades

Info

Publication number
CR20210586A
CR20210586A CR20210586A CR20210586A CR20210586A CR 20210586 A CR20210586 A CR 20210586A CR 20210586 A CR20210586 A CR 20210586A CR 20210586 A CR20210586 A CR 20210586A CR 20210586 A CR20210586 A CR 20210586A
Authority
CR
Costa Rica
Prior art keywords
diseases
sub
sup
treatment
pharmaceutical compositions
Prior art date
Application number
CR20210586A
Other languages
English (en)
Inventor
Christophe Peixoto
Denis Bucher
Taoues Temal-Laïb
Amynata Tirera
Béranger Duthion
Luke Jonathan Alvey
Nicolas Desroy
Florence Marie-Emilie Bonnaterre
Helène Marie Jary
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CR20210586A publication Critical patent/CR20210586A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención da a conocer compuestos según la Fórmula I: donde R<sup>1a</sup>, R<sup>1b</sup>, R<sup>1c</sup>, R<sup>2a</sup>, W<sub>1</sub>, W<sub>2</sub>, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, Y y Z son como se definen en el presente documento. La presente invención se refiere a compuestos, métodos para su producción, composiciones farmacéuticas que comprenden los mismos, y métodos de tratamiento que utilizan los mismos, para la profilaxis y/o tratamiento de enfermedades inflamatorias, enfermedades autoinflamatorias, enfermedades autoinmunitarias, enfermedades proliferativas, enfermedades fibróticas, rechazo de trasplantes, enfermedades que implican una alteración del recambio cartilaginoso, malformación congénita del cartílago, enfermedades que implican una alteración del recambio óseo, enfermedades asociadas a la hipersecreción de IL-6, enfermedades asociadas a la hipersecreción de TNFα, interferones, IL-12 y/o IL-23, enfermedades respiratorias, enfermedades endocrinas y/o metabólicas, enfermedades cardiovasculares, enfermedades dermatológicas, y/o enfermedades asociadas a la angiogénesis anormal mediante la administración del compuesto de la invención.
CR20210586A 2019-05-29 2020-05-25 Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades CR20210586A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1907616.5A GB201907616D0 (en) 2019-05-29 2019-05-29 Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
PCT/EP2020/064368 WO2020239658A1 (en) 2019-05-29 2020-05-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
CR20210586A true CR20210586A (es) 2022-01-24

Family

ID=67385363

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210586A CR20210586A (es) 2019-05-29 2020-05-25 Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades

Country Status (22)

Country Link
US (1) US20220340548A1 (es)
EP (1) EP3976189B1 (es)
JP (1) JP7550174B2 (es)
KR (1) KR20220015450A (es)
CN (1) CN113924146A (es)
AR (1) AR119028A1 (es)
AU (1) AU2020281650A1 (es)
BR (1) BR112021023900A2 (es)
CA (1) CA3141683A1 (es)
CL (1) CL2021003133A1 (es)
CO (1) CO2021017656A2 (es)
CR (1) CR20210586A (es)
EA (1) EA202193281A1 (es)
GB (1) GB201907616D0 (es)
IL (1) IL288375A (es)
MA (1) MA56019A (es)
MX (1) MX2021013803A (es)
PE (1) PE20220503A1 (es)
PL (1) PL3976189T3 (es)
SG (1) SG11202112652RA (es)
TW (1) TW202110839A (es)
WO (1) WO2020239658A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7360745B2 (ja) 2019-03-11 2023-10-13 インフラルクス ゲーエムベーハー Ｃ５ａ受容体の調節因子としての縮合ピペリジニル二環式化合物及び関連化合物
USD982434S1 (en) * 2021-08-31 2023-04-04 Level Up Dice LLC Dice storage container
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
AR128279A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
CN115304605B (zh) * 2022-01-21 2023-10-03 陕西国际商贸学院 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用
WO2024003209A1 (en) * 2022-07-01 2024-01-04 F. Hoffmann-La Roche Ag Imidazo[4,5-c]pyridine derivatives as sik modulators for the treatment of rheumatoid arthritis
WO2024104441A1 (en) * 2022-11-17 2024-05-23 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors and methods of uses thereof
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534206A (ja) 2007-07-20 2010-11-04 メルク・シャープ・エンド・ドーム・コーポレイション ピラゾロ［１，５−ａ］ピリミジン誘導体
CN103282034A (zh) * 2010-11-18 2013-09-04 利亘制药公司 造血生长因子模拟物的用途
EP2646215A1 (en) 2010-12-01 2013-10-09 Plasan Carbon Composites, Inc. Method and system for forming composite articles
EP2825540B1 (en) * 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CN106496222A (zh) 2016-09-07 2017-03-15 华东师范大学 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用
CN111433200B (zh) 2017-12-02 2024-03-22 加拉帕戈斯股份有限公司 用于治疗疾病的化合物及其药物组合物
CN108358894B (zh) * 2018-04-26 2021-05-07 四川大学 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用
US20220402911A1 (en) 2018-06-15 2022-12-22 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Also Published As

Publication number Publication date
CL2021003133A1 (es) 2022-07-22
PE20220503A1 (es) 2022-04-07
IL288375A (en) 2022-01-01
AU2020281650A1 (en) 2022-02-03
MX2021013803A (es) 2021-12-14
TW202110839A (zh) 2021-03-16
SG11202112652RA (en) 2021-12-30
CO2021017656A2 (es) 2022-01-17
US20220340548A1 (en) 2022-10-27
EP3976189B1 (en) 2024-07-03
EP3976189A1 (en) 2022-04-06
KR20220015450A (ko) 2022-02-08
PL3976189T3 (pl) 2024-09-09
EA202193281A1 (ru) 2022-03-01
WO2020239658A1 (en) 2020-12-03
JP7550174B2 (ja) 2024-09-12
CN113924146A (zh) 2022-01-11
EP3976189C0 (en) 2024-07-03
CA3141683A1 (en) 2020-12-03
MA56019A (fr) 2022-04-06
BR112021023900A2 (pt) 2022-01-18
AR119028A1 (es) 2021-11-17
GB201907616D0 (en) 2019-07-10
JP2022534578A (ja) 2022-08-02

Similar Documents

Publication Publication Date Title
MX2020005423A (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.
CR20210586A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades
MX2020013275A (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.
MX2020003863A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
WO2019173082A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
WO2019139899A8 (en) Benzamide compounds
MX2021011574A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2019015350A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis.
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
MY149577A (en) Cytokine inhibitors
PH12016501677B1 (en) Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
PH12019501853A1 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2023002522A (es) Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii.
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
MX2021011575A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MX2021010093A (es) Derivados de pirazolopiridina como inhibidores serina/treonina cinasa que contiene el dominio per-arnt-sim (pask).
MX2021008930A (es) Derivados de carbamato y sus usos.
MX2021012544A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.
WO2007041240A3 (en) Inhibitors of inflammatory cytokine transcription derived from hcmv protein ie2
WO2024020534A3 (en) Cyclic compounds and methods of using same
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria